Biomedical Advanced Research and Development Authority (BARDA)
330 C Street, SW
Room G640
Washington
D.C.
20201
United States
Tel: 202-260-1200
Fax: 202-205-4520
184 articles with Biomedical Advanced Research and Development Authority (BARDA)
-
Inflammatix Announces Additional $12.1 Million Funding From BARDA for ViraBac EZ Acute Infection Test
11/18/2021
Inflammatix announced today a contract extension of $12.1 million from the Biomedical Advanced Research and Development Authority (BARDA).
-
BD Collaborates with U.S. Government on Development of COVID-19 Combination Diagnostic Tests
10/28/2021
BD announced the formation of a strategic, public-private partnership with the Biomedical Advanced Research and Development Authority, part of the U.S. Health and Human Services Office of the Assistant Secretary for Preparedness and Response to support the development of a range of COVID-19 combination diagnostic tests for core laboratories, hospitals and at the point of care.
-
Peter Adams and Dave Harris at Rockies Venture Club (the oldest angel investment group in the U.S.) explored those myths and offered strategies to counter them.
-
T2 Biosystems Announces BARDA Exercise of Contract Option 2A Valued at $6.4 Million
10/4/2021
T2 Biosystems, Inc. announced that the Biomedical Advanced Research and Development Authority, part of the office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, has exercised contract Option 2A providing an additional $6.4 million of funding for the multiple year cost share contract between BARDA and T2 Biosystems.
-
Paratek Pharmaceuticals Announces Additional Funding Under the BARDA Contract to Advance the Development of NUZYRA® (omadacycline) for Post-Exposure Prophylaxis (PEP) and Treatment of Pulmonary Anthrax
9/27/2021
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the Biomedical Advanced Research and Development Authority (BARDA) has awarded an option under the Company’s Project BioShield contract.
-
BARDA and Partner Therapeutics foster a new partnership around their FDA-approved drug, Leukine® to improve patient care for sepsis patients
9/20/2021
Partner Therapeutics, Inc. (PTx) announced a collaboration with the Biomedical Advanced Research and Development Authority ( BARDA ) to advance a new diagnostic approach to select immunoparalyzed sepsis patients that could benefit most from Leukine (sargramostim).
-
SIGA Announces BARDA Exercise of Procurement Option Valued at $112.5 Million for Oral TPOXX®
9/13/2021
SIGA Technologies, Inc. announced the exercise of a procurement option under its 75A50118C00019 contract with Biomedical Advanced Research and Development Authority, part of the office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services for the delivery of oral TPOXX® treatment courses valued at approximately $112.5 million to the U.S. government.
-
Basilea awarded additional USD 4.3 million by BARDA to support phase 3 development of ceftobiprole
8/16/2021
Basilea Pharmaceutica Ltd. announced that it has been awarded an additional USD 4.3 million of non-dilutive funding by the Biomedical Advanced Research and Development Agency, part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, in the context of the existing contract to support the phase 3 program of Basilea’s antibiotic ceftobiprole.
-
The Trump White House removed Bright from his position at BARDA and reassigned him to a narrower role at the National Institutes of Health.
-
Paratek Pharmaceuticals Announces First BARDA Project BioShield Procurement of NUZYRA® (omadacycline) Valued at ~$38 Million-- First BARDA Procurement has been Delivered and Revenue will be Recognized in Second Quarter 2021
6/29/2021
Paratek Pharmaceuticals, Inc. today announced Paratek has delivered the first procurement of NUZYRA to the Biomedical Advanced Research and Development Authority (BARDA).
-
MediciNova to Conduct Mouse Study under Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury
6/28/2021
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange, announced it will conduct a mouse study to investigate the efficacy of MN-166 in a murine model of chlorine-induced lung injury and lethality.
-
Public Health Vaccines Awarded First Options Under Advanced Development Contract From BARDA to Continue Development of Vaccine Against Marburg Virus
6/23/2021
Public Health Vaccines, LLC, a biotechnology company out of Cambridge, MA, has been awarded the first two options under its Biomedical Advanced Research and Development Authority contract for the advanced development of its vaccine candidate designed to prevent Marburg virus infections.
-
The product is designed to help heal patients who have received thermal burns that would ultimately require a skin graft.
-
An ugly symbol of racism appears to have reared its head at a Merck facility in North Carolina. The pharma giant is investigating reports of a noose found hanging at a construction project on the 262-acre facility.
-
MediciNova Initiates Sheep Study under Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury
6/7/2021
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange, announced it has initiated a sheep study to investigate MN-166 in an ovine model of chlorine-induced acute lung injury.
-
The nation’s top science adviser believes the country’s renewed enthusiasm for science may pave the way for plug-and-play vaccines that can nullify the next pandemic before it starts.
-
A two-stage Phase III clinical trial by Sanofi and GSK, is studying a COVID-19 vaccine candidate targeting the original SARS-CoV-2 strain as well as the South African B.1.351 variant.
-
Sepsis is among the best-known and least effectively treated conditions in the modern world. The standard of care has failed for these infections, leaving the U.S. healthcare system with $62 billion and 270,000 deaths annually. Globally, 11 million die from sepsis each year. Effective drugs and d...
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 23, 2021.
-
AMRI Included in BARDA CDMO Network in Support of COVID-19 Pandemic Response in the U.S.
1/11/2021
AMRI Included in BARDA CDMO Network in Support of COVID-19 Pandemic Response in the U.S.